Trump speeds psychedelic research

In a significant shift in federal drug policy, President Donald Trump has directed the FDA to fast-track research into psychedelic-based therapies.

The executive order allocates $50 million for studies into ibogaine, a plant-based psychedelic that military veteran groups claim is highly effective for treating post-traumatic stress disorder.

The policy change was reportedly sparked by a text exchange between the President and Joe Rogan, leading to a rapid White House push to ease restrictions.

While some medical experts welcome the research, others warn of potential heart risks and the need for rigorous clinical trials before widespread use.